Is FDA Listening Enough to Patients? Agency Wants Feedback!

When Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA) into law in 2012, its patient-centered provisions were among the biggest changes set to impact the culture of the US Food and Drug Administration (FDA).  Now, two years later and with major planning already underway regarding the future of FDA’s patient-centered activities, agency regulators are reaching out to the public to ask what more they can do to improve their efforts.

FDA awards grants to stimulate drug, device development for rare diseases

The U.S. Food and Drug Administration announced in September 2014 The FDA awards grants for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products for patients with rare diseases, with at least a quarter of the funding going to studies focused solely on pediatrics.